US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...
Amgen gets expanded FDA label approval for Uplizna
Amgen ( NASDAQ: NASDAQ: AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label ...
FDA Approves Second Indication for Amgen's Immune System Treatment Uplizna
Amgen said the Food and Drug Administration approved Uplizna for Immunoglobulin G4-related disease, the second approved indication. The biotechnology company said Thursday the FDA granted breakthrough ...
UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4 ...
US FDA approves expanded use of Amgen's rare disease drug
The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...
Amgen stock rises following FDA approval of UPLIZNA
The FDA’s decision to grant Breakthrough Therapy Designation to UPLIZNA underscores the significant unmet medical need in ...
AbbVie cuts 2025 profit forecast on acquisition expenses
AbbVie on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in ...
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
BioSpace3d
FDA Action Alert: Amgen, Aldeyra and Argenx
In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.
The American Journal of Managed Care2d
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...
Le Lézard1h
Careington Announces the Expansion of Savings Plans Available Through Its Employer Enrollment Portal
Careington International Corporation is proud to expand its suite of plan options available through Careington Direct, its self-service web portal created to be a single-source solution for small ...